Five-year collaboration continues support for the DNA Damage Response Consortium and broader NBTS initiatives
National Brain Tumor Society (NBTS), the largest patient advocacy organization in the United States dedicated to the brain tumor community, today announced the renewal of its strategic collaboration with IQVIA, a leading global provider of clinical research services, commercial insights and health care intelligence to the life sciences and health care industries. The collaboration will continue supporting research, community engagement, and initiatives designed to accelerate the development of new treatments for people living with brain tumors.
Since initially partnering in 2022, IQVIA has supported several NBTS mission-delivery programs, with a focus on helping advance innovative approaches to brain tumor treatment through NBTS’s DNA Damage Response Consortium — a research initiative that brings together leading adult and pediatric investigators to evaluate therapies targeting a tumor’s DNA damage response network.
“Renewing our collaboration with IQVIA reflects the strong progress we’ve made together and our shared commitment to advancing science for patients with brain tumors,” said David F. Arons, President and Chief Executive Officer of the National Brain Tumor Society. “IQVIA’s expertise in clinical research and health data science complements NBTS’s leadership in research collaboration and patient advocacy, enabling us to accelerate promising discoveries and move them closer to patients. Through this renewed commitment, NBTS and IQVIA will continue building on the momentum of the past several years — expanding opportunities for collaboration across academia, industry and the patient community to accelerate breakthroughs in neuro-oncology.”
The collaboration has already contributed to broad progress across the NBTS research portfolio, including in targeted therapies, immunotherapy approaches and initiatives that integrate patient and caregiver perspectives into the development of new treatments. Through the DNA Damage Response Consortium, the collaboration has contributed to several key advances as consortium investigators have progressed multiple therapeutic strategies toward clinical evaluation.
IQVIA is also involved across several key initiatives that strengthen the broader neuro-oncology ecosystem. Leaders from IQVIA regularly contribute their expertise through NBTS programs such as the Research Roundtable, a cross-sector forum that brings together academic researchers, regulators, industry partners, and patient advocates to address challenges in brain tumor drug development and identify strategies to accelerate progress.
The collaboration supports NBTS efforts to engage the brain tumor community and build knowledge about how innovation is occurring to bring about transformative new therapies, including IQVIA participation in several NBTS initiatives and events, including Glioblastoma Awareness Day.
“IQVIA is proud to continue our collaboration with the National Brain Tumor Society and the broader brain tumor community,” said Peter Ronco, senior vice president and president of IQVIA Biotech. “By combining NBTS’s leadership in patient advocacy and research collaboration with IQVIA’s capabilities in clinical development and health data science, we can help advance innovative therapies and improve outcomes for patients facing these devastating diseases.”
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and health care intelligence to the life sciences and health care industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high quality health data, Health care grade AI®, advanced analytics, the latest technologies, and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability, and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in health care, life sciences, data science, technology, and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps health care stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other health care stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About the National Brain Tumor Society
Building on over 30 years of experience, the National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes, and unites the brain tumor community to discover a cure, deliver effective treatments, and advocate for patients and caregivers. Our focus on defeating brain tumors and improving the quality of patients’ lives is powered by our partnerships across the science, health care, policy, and business sectors. We fund treatments-focused research and convene those most critical to curing brain tumors — once and for all. Learn more at BrainTumor.org.
